Management of osteoporosis among the elderly with other chronic medical conditions

Drugs and Aging

Volumn 29, Issue 7, 2012, Pages 549-564

  Curtis, Jeffrey R ^a   Safford, Monika M ^b  

^a University of Alabama at Birmingham   (United States)

^b University of Alabama at Birmingham   (United States)

Author keywords

Elderly; Fracture; Osteoporosis

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; DENOSUMAB; ERGOCALCIFEROL; IBANDRONIC ACID; PARATHYROID HORMONE[1-34]; PLACEBO; RALOXIFENE; RISEDRONIC ACID; STRONTIUM RANELATE; VITAMIN D; ZOLEDRONIC ACID;

ALCOHOLISM; BONE DENSITY; CALCIUM DEFICIENCY; COMORBIDITY; DEMENTIA; DRUG TOLERABILITY; DUAL ENERGY X RAY ABSORPTIOMETRY; ELDERLY CARE; FRAGILITY FRACTURE; GASTROINTESTINAL SYMPTOM; HEALTH CARE QUALITY; HIP FRACTURE; HOT FLUSH; HUMAN; LIFE EXPECTANCY; LONG TERM CARE; MEDICARE; MORBIDITY; MORTALITY; NOSE IRRITATION; OSTEOPOROSIS; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; SMOKING; VERTEBRA FRACTURE; VITAMIN D DEFICIENCY;

AGED; ANIMALS; CHRONIC DISEASE; HUMANS; OSTEOPOROSIS; QUALITY OF HEALTH CARE; RISK;

EID: 84862904793     PISSN: 1170229X     EISSN: 11791969     Source Type: Journal    
DOI: 10.2165/11599620-000000000-00000     Document Type: Review

References (103)

1. Prevention and management of osteoporosis. World Health Organ Tech Rep Ser 2003; 921: 1-164
2. National Osteoporosis Foundation (NOF). Clinician's guide to prevention and treatment of osteoporosis. Washington, DC: NOF, 2010 [online]. Available from URL: http://www.nof.org/sites/default/files/pdfs/NOF-ClinicianGuide2009-v7. pdf [Accessed 2011 Aug 18]
3. Burge R, Dawson-Hughes B, Solomon DH, et al. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res 2007; 22: 465-75 (Pubitemid 46797130)
4. Rosamond W, Flegal K, Furie K, et al. Heart disease and stroke statistics - 2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2008; 117: e25-146
5. Lloyd-Jones D, Adams RJ, Brown TM, et al. Heart disease and stroke statistics-2010 update: a report from the American Heart Association. Circulation 2010; 121: e46-215
6. American Cancer Society. Cancer Facts & Figures 2010. Atlanta (GA): American Cancer Society, 2010 [online]. Available from URL: http://www.cancer. org/acs/groups/content/@nho/documents/document/acspc-024113.pdf [Accessed 2011 Aug 10]
7. Curtis JR, Arora T, Matthews RS, et al. Is withholding osteoporosis medication after fracture sometimes rational? A comparison of the risk for second fracture versus death. J Am Med Dir Assoc 2010; 11: 584-91
8. Boonen S, Dejaeger E, Vanderschueren D, et al. Osteoporosis and osteoporotic fracture occurrence and prevention in the elderly: a geriatric perspective. Best Pract Res Clin Endocrinol Metab 2008; 22: 765-85
9. Cummings SR, Melton LJ. Epidemiology and outcomes of osteoporotic fractures. Lancet 2002; 359: 1761-7
10. Hallberg I, Rosenqvist AM, Kartous L, et al. Health-related quality of life after osteoporotic fractures. Osteoporos Int 2004; 15: 834-41 (Pubitemid 39361955)
11. Sanders KM, Nicholson GC, Watts JJ, et al. Half the burden of fragility fractures in the community occur in women without osteoporosis. When is fracture prevention cost-effective? Bone 2006; 38: 694-700
12. Dawson-Hughes B, Tosteson AN, Melton 3rd LJ, et al., National Osteoporosis Foundation Guide Committee. Implications of absolute fracture risk assessment for osteoporosis practice guidelines in the USA. Osteoporos Int 2008; 19: 449-58
13. Van den Bergh JP, van Geel TA, Lems WF, et al. Assessment of individual fracture risk: FRAX and beyond. Curr Osteoporos Rep 2010; 8: 131-7
14. Vondracek SF, Linnebur SA. Diagnosis and management of osteoporosis in the older senior. Clin Interv Aging 2009; 4: 121-36
15. Nguyen ND, Frost SA, Center JR, et al. Development of prognostic nomograms for individualizing 5-year and 10-year fracture risks. Osteoporos Int 2008; 19: 1431-44
16. Berg KM, Kunins HV, Jackson JL, et al. Association between alcohol consumption and both osteoporotic fracture and bone density. Am J Med 2008; 121: 406-18 (Pubitemid 351626009)
17. Peppone LJ, Hebl S, Purnell JQ, et al. The efficacy of calcitriol therapy in the management of bone loss and fractures: a qualitative review. Osteoporos Int 2010; 21: 1133-49
18. Katz S, Weinerman S. Osteoporosis and gastrointestinal disease. Gastroenterol Hepatol (N Y) 2010; 6: 506-17
19. VanderWalde A, Hurria A. Aging and osteoporosis in breast and prostate cancer. CA Cancer J Clin 2011; 61: 139-56
20. Pitts CJ, Kearns AE. Update on medications with adverse skeletal effects. Mayo Clin Proc 2011; 86: 338-43
21. Boyd CM, Darer J, Boult C, et al. Clinical practice guidelines and quality of care for older patients with multiple comorbid diseases: implications for pay for performance. JAMA 2005; 294: 716-24 (Pubitemid 41159291)
22. Anderson G, Horvath J. Chronic conditions: making the case for ongoing care. Baltimore (MD): Johns Hopkins University, 2002 Dec [online]. Available from URL: http://www.partnershipforsolutions.org/DMS/files/chronicbook2002.pdf [Accessed 2011 Aug 10]
23. Gillespie L, Handoll H. Prevention of falls and fall-related injuries in older people. Inj Prev 2009; 15: 354-5
24. Boonen S, Lips P, Bouillon R, et al. Need for additional calcium to reduce the risk of hip fracture with vitamin D supplementation: evidence from a comparative meta-analysis of randomized controlled trials. J Clin Endocrinol Metab 2007; 92: 1415-23 (Pubitemid 46556419)
25. Avenell A, Gillespie WJ, Gillespie LD, et al. Vitamin D and vitamin D analogues for preventing fractures associated with involutional and post-menopausal osteoporosis. Cochrane Database Syst Rev 2009; (2): CD000227
26. Latham NK, Anderson CS, Lee A, et al. A randomized, controlled trial of quadriceps resistance exercise and vitamin D in frail older people: the frailty interventions trial in elderly subjects (FITNESS). J Am Geriatr Soc 2003; 51: 291-9 (Pubitemid 36348889)
27. Porthouse J, Cockayne S, King C, et al. Randomized controlled trial of calcium and supplementation with cholecalciferol (vitamin D3) for prevention of fractures in primary care. BMJ 2005; 330: 1-6
28. Grant AM, Avenell A, Campbell MK, et al. Oral vitamin D3 and calcium for secondary prevention of low-trauma fractures in elderly people (randomized evaluation of calcium or vitamin D, RECORD): a randomized placebo-controlled trial. Lancet 2005; 365: 1621-8 (Pubitemid 40693411)
29. Jackson RD, LaCroix AZ, Gass M, et al. Calcium plus vitamin D supplementation and risk of fractures. N Engl J Med 2006; 354: 669-83 (Pubitemid 43247138)
30. Law M, Withers H, Morris J, et al. Vitamin D supplementation and the prevention of fractures and falls: results of a randomized trial in elderly people in residential accommodation. Age Ageing 2006; 35: 482-6 (Pubitemid 44295635)
31. Lyons RA, Johansen A, Brophy S, et al. Preventing fractures among older people living in institutional care: a pragmatic randomised double blind placebo controlled trial of vitamin D supplementation. Osteoporos Int 2007; 18: 811-8 (Pubitemid 46684786)
32. Annweiler C, Montero-Odasso M, Schott AM, et al. Fall prevention and vitamin D in the elderly: an overview of the key role of the non-bone effects. J Neuroeng Rehabil 2010; 7: 50
33. Ip TP, Leung J, Kung AW. Management of osteoporosis in patients hospitalized for hip fractures. Osteoporos Int 2010; 21 Suppl. 4: S605-14
34. Gates S, Fisher JD, Cooke MW, et al. Multifactorial assessment and targeted intervention for preventing falls and injuries among older people in community and emergency care settings: systematic review and meta-analysis. BMJ 2008; 336: 130-3 (Pubitemid 351211964)
35. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996; 348: 1535-41 (Pubitemid 26411651)
36. Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998; 280: 2077-82 (Pubitemid 29014065)
37. Pols HA, Felsenberg D, Hanley DA, et al. Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Fosamax International Trial Study Group. Osteoporos Int 1999; 9: 461-8 (Pubitemid 29231740)
38. Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. JAMA 1999; 282: 1344-52 (Pubitemid 29483192)
39. Reginster J, Minne HW, Sorensen OH, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 2000; 11: 83-91 (Pubitemid 30099515)
40. McClung M, Geusens P, Miller PD, et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 2001; 344: 333-40 (Pubitemid 32107641)
41. Chesnut 3rd CH, Skag A, Christiansen C, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004; 19: 1241-9 (Pubitemid 41094364)
42. Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007; 356: 1809-22 (Pubitemid 46698462)
43. Lyles KW, Colón-Emeric CS, Magaziner JS, et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 2007; 357: 1799-809 (Pubitemid 350044800)
44. Chesnut 3rd CH, Silverman S, Andriano K, et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the Prevent Recurrence of Osteoporotic Fractures study. PROOF Study Group. Am J Med 2000; 109: 267-76
45. Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 1999; 282: 637-45 (Pubitemid 29384151)
46. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001; 344: 1434-41 (Pubitemid 32402100)
47. Meunier PJ, Roux C, Seeman E, et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 2004; 350: 459-68 (Pubitemid 38133766)
48. Reginster JY, Seeman E, De Vernejoul MC, et al. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J Clin Endocrinol Metab 2005; 90: 2816-22 (Pubitemid 40686329)
49. Seeman E, Vellas B, Benhamou C, et al. Strontium ranelate reduces the risk of vertebral and nonvertebral fractures in women eighty years of age and older. J Bone Miner Res 2006; 21: 1113-20
50. Pageau SC. Denosumab. MAbs 2009; 1: 210-5
51. Brown JP, Prince RL, Deal C, et al. Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. J Bone Miner Res 2009; 24: 153-61
52. Cummings SR, San Martin J, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009; 361: 756-65
53. Boonen S, Black DM, Colón-Emeric CS, et al. Efficacy and safety of a once-yearly intravenous zoledronic acid 5 mg for fracture prevention in elderly postmenopausal women with osteoporosis aged 75 and older. J Am Geriatr Soc 2010; 58: 292-9
54. Boonen S, McClung MR, Eastell R, et al. Safety and efficacy of risedronate in reducing fracture risk in osteoporotic women aged 80 and older: implications for the use of antiresorptive agents in the old and oldest old. J Am Geriatr Soc 2004; 52: 1832-9 (Pubitemid 41710266)
55. Boonen S, Marin F, Mellstrom D, et al. Safety and efficacy of teriparatide in elderly women with established osteoporosis: bone anabolic therapy from a geriatric perspective. J Am Geriatr Soc 2006; 54: 782-9 (Pubitemid 44030200)
56. Bock O, Felsenberg D. Bisphosphonates in the management of postmenopausal osteoporosis-optimizing efficacy in clinical practice. Clin Interv Aging 2008; 3: 279-97 (Pubitemid 352037868)
57. Wells GA, Cranney A, Peterson J, et al. Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev 2008; (1): CD001155
58. Wells GA, Cranney A, Peterson J, et al. Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev 2008; (1): CD004523
59. Abrahamsen M, Eiken P, Eastell R. Proton pump inhibitor use and the antifracture efficacy of alendronate. Arch Intern Med 2011; 171: 998-1004
60. Delmas PD, Benhamou CL, Man Z, et al. Monthly dosing of 75 mg risedronate on 2 consecutive days a month: efficacy and safety results. Osteoporos Int 2008; 19: 1039-45
61. Black DM, Schwartz AV, Ensrud KE, et al. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 2006; 296: 2927-38 (Pubitemid 46021497)
62. Mellström DD, Sörensen OH, Goemaere S, et al. Seven years of treatment with risedronate in women with postmenopausal osteoporosis. Calcif Tissue Int 2004; 75: 462-8 (Pubitemid 40174503)
63. Lewiecki EM. Safety of long-term bisphosphonate therapy for the management of osteoporosis.Drugs 2011; 71: 791-814
64. Armamento-Villareal R, Napoli N, Panwar V, et al. Suppressed bone turnover during alendronate therapy for high-turnover osteoporosis. N Engl J Med 2006; 355: 2048-50 (Pubitemid 44708036)
65. Lee P, van der Wall H, Seibel MJ. Looking beyond low bone mineral density: multiple insufficiency fractures in a woman with post-menopausal osteoporosis on alendronate therapy. J Endocrinol Invest 2007; 30: 590-7 (Pubitemid 47577812)
66. Lenart BA, Lorich DG, Lane JM. Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate. N Engl J Med 2008; 358: 1304-6 (Pubitemid 351439247)
67. Mashiba T, Hirano T, Turner CH, et al. Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib. J Bone Miner Res 2000; 15: 613-20 (Pubitemid 30174014)
68. Visekruna M, Wilson D, McKiernan FE. Severely suppressed bone turnover and atypical skeletal fragility. J Clin Endocrinol Metab 2008; 93: 2948-52
69. Armamento-Villareal R, Napoli N, Diemer K, et al. Bone turnover in bone biopsies of patients with low-energy cortical fractures receiving bisphosphonates: a case series. Calcif Tissue Int 2009; 85: 37-44
70. Goh SK, Yang KY, Koh JS, et al. Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution. J Bone Joint Surg Br 2007; 89: 349-53 (Pubitemid 46563912)
71. Lenart BA, Neviaser AS, Lyman S, et al. Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control study. Osteoporos Int 2009; 20: 1353-62
72. Abrahamsen B, Eiken P, Eastell R. Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register-based national cohort study. J Bone Miner Res 2009; 24: 1095-102
73. Shane E, Burr D, Ebeling PR, et al. Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2010; 25: 2267-94
74. Sellmeyer DE. Atypical fractures as a potential complication of long-term bisphosphonate therapy. JAMA 2010; 304: 1480-4
75. Wysowski DK. Reports of esophageal cancer with oral bisphosphonate use [letter]. N Engl J Med 2009; 360: 89-90
76. Abrahamsen B, Eiken P, Eastell R. More on reports of esophageal cancer with oral bisphosphonate use [letter]. N Engl J Med 2009; 360: 1789
77. Solomon DH, Patrick A, Brookhart MA. More on reports of esophageal cancer with oral bisphosphonate use [letter]. N Engl J Med 2009; 360: 1789-90
78. FDA Drug Safety Communication: Ongoing safety review of oral osteoporosis drugs (bisphosphonates) and potential increased risk of esophageal cancer. Rockville (MD): FDA, 2011 Jul 21 [online]. Available from URL: http://www.fda.gov/Drugs/DrugSafety/ucm263320.htm [Accessed 2011 Nov 14]
79. Papapetrou PD. Bisphosphonate-associated adverse events. Hormones (Athens) 2009; 8: 96-110
80. Actonel® (risedronate sodium) tablets: US prescribing information. Rockaway (NJ): Warner Chilcott (US), LLC, 2011
81. Evista: US prescribing information. Indianapolis (IN): Lilly USA, LLC, 2011 Jan 7 [online]. Available from URL: http://pi.lilly.com/us/evista-pi.pdf [Accessed 2011 Nov 15]
82. Barrett-Connor E, Mosca L, Collins P, et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 2006; 355: 125-37 (Pubitemid 44050394)
83. Curtis JR, Carbone L, Cheng H, et al. Longitudinal trends in use of bone mass measurement among older Americans, 1999-2005. J Bone Miner Res 2008; 23: 1061-7 (Pubitemid 351915728)
84. Miacalcin: US prescribing information. East Hanover (NJ): Novartis, 2011 [online]. Available from URL: http://www.pharma.us.novartis.com/product/pi/pdf/ miacalcin-nasal.pdf [Accessed 2011 Nov 15]
85. Forteo: US prescribing information. Indianapolis (IN): Lilly USA, LLC, 2010 [online]. Available from URL: http://pi.lilly.com/us/forteo-pi.pdf [Accessed 2011 Nov 15]
86. National Committee for Quality Assurance. The state of health care quality 2007. Washington, DC: National Committee for QualityAssurance, 2007 [online].Available fromURL: http://www.ncqa.org/Portals/0/Publications/ Resource%20Library/SOHC/SOHC-07.pdf [Accessed 2011 Aug 10]
87. Curtis JR, Kim Y, Bryant T, et al. Osteoporosis in the home health care setting: a window of opportunity? Arthritis Rheum 2006; 55: 971-5 (Pubitemid 44917473)
88. Zimmerman SI, Girman CJ, Buie VC, et al. The prevalence of osteoporosis in nursing home residents. Osteoporos Int 1999; 9: 151-7 (Pubitemid 29219077)
89. Greenspan SL, Schneider DL, McClung MR, et al. Alendronate improves bone mineral density in elderly women with osteoporosis residing in long-term care facilities: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 2002; 136: 742-6 (Pubitemid 34525673)
90. Parikh S, Avorn J, Solomon DH. Pharmacological management of osteoporosis in nursing home populations: a systematic review. J Am Geriatr Soc 2009; 57: 327-34
91. Colón-Emeric C, Casebeer L, Saag K, et al. Barriers to providing osteoporosis care in skilled nursing facilities: perceptions of medical directors and directors of nursing. J Am Med Dir Assoc 2005; 6 (3 Suppl.): S61-6
92. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of randomised trials. Lancet 1998; 351: 1451-67
93. Messerli F, Pinto L, Tang SS, et al. Impact of systemic hypertension on the cardiovascular benefits of statin therapy: a meta-analysis. Am J Cardiol 2008; 101: 319-25 (Pubitemid 351162960)
94. Arias E. National Vital Statistics Report: United States life tables, 2003. Department of Health and Human Services. Centers for Disease Control and Prevention. National Center for Health Statistics [online]. Available from URL: http://www.cdc.gov/nchs/data/statab/lewk3-2003.pdf [Accessed 2011 Aug 10]
95. Maricic M, Adachi JD, Sarkar S, et al. Early effects of raloxifene on clinical vertebral fractures at 12 months in postmenopausal women with osteoporosis. Arch Intern Med 2002; 162: 1140-3 (Pubitemid 34522401)
96. Roux C, Seeman E, Eastell R, et al. Efficacy of risedronate on clinical vertebral fractures within six months. Curr Med Res Opin 2004; 20: 433-9 (Pubitemid 38525150)
97. Fojo T, Grady C. How much is life worth: cetuximab, non-small cell lung cancer, and the $440 billion question. J Natl Cancer Inst 2009; 101: 1044-8
98. Freemantle N, Cleland J, Young P, et al. Beta blockade after myocardial infarction: systematic review and meta regression analysis. BMJ 1999; 318: 1730-7 (Pubitemid 29290470)
99. Adachi JD, Lyles KW, Colón-Emeric CS, et al. Zoledronic acid results in better health-related quality of life following hip fracture: the HORIZON-Recurrent Fracture Trial. Osteoporos Int. Epub 2011 Jan 20. doi: 10.1007/s00198-010-1514-9
100. Tosi LL, Gliklich R, Kannan K, et al. The American Orthopaedic Association's "own the bone" initiative to prevent secondary fractures. J Bone Joint Surg Am 2008; 90: 163-73
101. Feldstein A, Elmer PJ, Smith DH, et al. Electronic medical record reminder improves osteoporosis management after a fracture: a randomized, controlled trial. J Am Geriatr Soc 2006; 54: 450-7 (Pubitemid 43327157)
102. Centers for Medicare & Medicaid Services. The 2010 Physician Quality Reporting Initiative measures list [online]. Available from URL: https://www.cms.gov/PQRS/Downloads/2010-PQRI-MeasuresList-111309.pdf [Accessed 2011 Aug 10]
103. Lewiecki EM, Baim S, Siris ES. Osteoporosis care at risk in the United States. Osteoporos Int 2008; 19: 1505-9